Clinical studies across multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC), colon cancer, and breast cancer, have consistently demonstrated that increased infiltration of MARCO+ TAMs correlates with poor patient prognosis [17–21]. This evidence concerns the gene MARCO and breast cancer.